首页> 外文期刊>Antimicrobial agents and chemotherapy. >In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from US Hospitals: Results from Seven Years of the AWARE Surveillance Program ( 2010 to 2016)
【24h】

In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from US Hospitals: Results from Seven Years of the AWARE Surveillance Program ( 2010 to 2016)

机译:来自美国医院的Ceftarline和比较器的体外活动来自美国医院的肺炎群岛分离株:结果来自意识监督计划的七年(2010年至2016年)

获取原文
获取原文并翻译 | 示例
           

摘要

We evaluated trends in Streptococcus pneumoniae antimicrobial susceptibility in United States hospitals in the 2010 to 2016 period. A total of 8,768 clinical isolates from 47 medical centers were tested for susceptibility by broth microdilution methods. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) rates decreased from 25.7% and 12.4%, respectively, in 2010 to 17.7% and 3.6%, respectively, in 2016. The susceptibilities to most comparator antimicrobial agents increased, whereas the susceptibilities to ceftaroline, levofloxacin, linezolid, and tigecycline remained stable. Ceftaroline retained potent activity against S. pneumoniae ( 99.9%) with no marked variations.
机译:我们在2010年至2016年期间评估了美国医院的链球菌抗菌敏感性的趋势。 通过肉汤微脱离方法测试了47个医疗中心的8,768个临床分离株。 多药物(MDR)和广泛的耐药性(XDR)率分别在2010年分别从25.7%和12.4%下降到2016年的17.7%和3.6%。对大多数比较剂抗菌剂的敏感性增加,而且 对Ceftaroline,左氧氟沙星,LINZOLID和TIGECOLINE的敏感性保持稳定。 Ceftaroline在没有明显的变异的情况下保留针对肺炎肺炎(99.9%)的有效活性。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号